AptarGroup, Inc. develops drug delivery and consumer-product dosing, dispensing and protection technologies for pharmaceutical, beauty, food, beverage, personal care and home care markets. News about ATR commonly covers operating results across Pharma, Beauty and Closures, demand trends in prescription drug delivery, biologics, injectables, nasal delivery, fragrance dispensing and closure applications.
Company updates also include product introductions such as inverted lidless dispensing closures using SimpliSqueeze® valve technology, Aptar Pharma delivery systems used in clinical-stage nasal therapies, Aptar Digital Health partnerships, dividend declarations, share repurchases and investor presentations.
AptarGroup (ATR) reported third-quarter sales of $1.02 billion, with revenue growth across all three segments but lower earnings. Sales rose 6% year over year, while core sales, excluding currency and acquisition/deconsolidation effects, increased 5%. Net income was $33 million; reported earnings per share fell to $0.51 from $1.92. Loss of control of its Russian subsidiary led to deconsolidation, with related impacts totaling $60.4 million after tax, or $0.94 per diluted share.
Adjusted EPS was $1.52 versus $1.62 at comparable exchange rates, and adjusted EBITDA margin fell to 21.3% from 23.2%. Nine-month sales rose 8% to $3.03 billion, while reported EPS declined 37% to $3.00. Aptar expects fourth-quarter adjusted EPS of $1.39–$1.47. The quarterly dividend increased from $0.48 to $0.50 per share, payable December 3, 2026; shareholder returns totaled $272 million year to date.
AptarGroup (ATR) increased its quarterly cash dividend to $0.50 per share, payable December 3, 2026, following board approval. The dividend is approximately 4% higher than the previous $0.48 per share and is payable to stockholders of record on November 12, 2026. The company said the increase puts it on track for its 33rd consecutive year of paying an annually increasing dividend.
AptarGroup (NYSE: ATR), through Aptar Pharma, announced a collaboration with Stevanato Group to evaluate pre-filled syringe components as assembled systems. The work combines Stevanato glass syringes with Aptar Pharma plungers and rigid needle shields for sensitive biologics and other injectable therapies.
Testing covers 1 mL long and 2.25 mL formats, examining component forces and seal integrity. Aptar Pharma aims to provide earlier data to inform packaging selection and support customers in meeting USP <382> requirements. Data packages and regulatory support services are available. The collaboration builds on Aptar Pharma’s system-level framework launched in July 2026.
Aptar (ATR), through Aptar Pharma, has acquired PULMOTREE, a Munich-based company specializing in drug delivery to the lungs. Aptar expects the acquisition to accelerate development, industrialization and commercialization of PULMOTREE’s Kolibri Non-Propellant Liquid Inhaler platform and expand its respiratory drug delivery opportunities, including delivery of complex molecules such as biologics.
Aptar Pharma plans to combine Kolibri with its formulation development, device development, regulatory, manufacturing and commercial capabilities to support pharmaceutical partners from development through clinical evaluation and market launch. The company also expects opportunities to deepen customer relationships and capture greater value across the drug development lifecycle by drawing on services from Nanopharm, Noble and Aptar Digital Health.
AptarGroup (ATR) appointed Virginie Maes as President of its Aptar Pharma business, effective January 1, 2027.
Maes joins from Amcor, where she currently leads the global Flexibles Pharma and Medical packaging business across North America, Latin America, EMEA and Asia. Her previous Amcor leadership roles covered pharma, medical, strategy and business development.
AptarGroup (ATR) announced CE marking for its LuerVax intranasal vaccine delivery device and accompanying Spray Divider under European medical-device rules. The marking indicates that both meet the European general safety and performance requirements for medical devices under the EU Medical Device Regulation.
LuerVax is a Class I, non-sterile, single-use device intended for vaccine administration by healthcare professionals with a compatible LuerLock syringe. The optional Spray Divider enables two sequential sprays, one per nostril. Aptar says the CE-marked platform expands its support for vaccine developers from early clinical studies through commercialization.
Aptar (ATR) signed a research collaboration agreement with Massachusetts General Hospital, led by Alice Stanton, PhD, to develop a predictive, data-driven model for nose-to-brain (N2B) drug delivery.
The partners will build an integrated translational platform that combines in vitro, in vivo and computational technologies to characterize mechanisms, pathways and kinetics of N2B transport across a wide range of molecular classes and physicochemical properties. The project aims to create an N2B New Approach Methodologies (NAM) tool that screens compounds for suitability for intranasal delivery to the brain, informs formulation and device design, and incorporates Aptar’s nasal systems, including its Cerespray™ and Neurospray™ platforms, to support future central nervous system therapy development.
Summary not available.
Aptar (NYSE: ATR) has been named one of the World’s Most Sustainable Companies 2026 by TIME for the third consecutive year, ranking 261 out of 750 companies evaluated with Statista. The ranking assessed over 5,000 firms on transparency, environmental and social stewardship, and alignment with UN Global Compact or Science Based Targets.
According to Aptar, its 2025 sustainability progress includes 98% of electricity from renewable sources, validated Scope 1, 2 and 3 emissions targets by the Science Based Targets initiative, a CSRD-aligned double materiality assessment, CDP A List recognition and Gold EcoVadis status, placing it in the top 5% of rated companies.
Aptar Beauty (NYSE:ATR) announced the first commercial launch of its NeoDropper Autoload auto-loading, dosing dropper technology, featured on Dermalogica’s new FutureCode Booster skincare serum. The system targets prestige skincare and dermocosmetic brands, focusing on dosage control, convenience, hygiene and clean usage.
NeoDropper Autoload combines a twist-and-push mechanism with an auto-loading cap that delivers a consistent dose after each use. Its short applicator is designed to reduce breakage and improve hygiene, while a dip tube helps consumers use formula down to the last drop, minimizing waste. Dermalogica reports positive consumer feedback on dispensing performance, ease of use and user experience, extending a longstanding packaging innovation collaboration with Aptar.